Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis

Rhinitis Clinical Trial

Official title:

Multicenter, Phase III, Randomized, Open, Parallel, Comparative to Evaluate the Efficacy and Safety of the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis and Allergic Reactions, in Pediatric Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01393548
• Other study ID #: ACH-DCN-03(03/10)
• Status: Completed
• Phase: Phase 3
• First received: October 27, 2010
• Last updated: January 12, 2017
• Start date: August 2014
• Est. completion date: December 2016

Study information

• Verified date: January 2017
• Source: Ache Laboratorios Farmaceuticos S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter clinical trial, phase III, non-inferiority, controlled by active medicine, open, randomized, enroll 538 children, 2 to 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.

Description:

This study evaluate the efficacy and safety of experimental drug The study was designed to evaluate the efficacy and safety of fixed combinations Decongex® Plus Syrup and Decongex® Plus Oral Solution (consisting of brompheniramine maleate and phenylephrine hydrochloride) compared to Resfenol® Oral Solution (paracetamol, maleate chlorpheniramine and phenylephrine hydrochloride) in the treatment of nasal congestion and rhinorrhea present in acute attacks of viral rhinitis (common cold) and allergic. This study population will consist in participants of both sexes, aged between 6 to 11 years old with acute inflammatory condition of the upper airways, defined as nasal congestion and runny nose, with no less than 24 (twenty four) hours and a maximum of 48 (forty-eight) hours prior to inclusion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 879
• Est. completion date: December 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 12 Years

Eligibility

Inclusion Criteria:

1. Patients between 2 and 12 years old, of both sexes. Must be responsible be able to understand and provide ICF and able to allow compliance to treatment and protocol requirements, fulfilling the regular visits;

2. Patients with symptoms of acute inflammation upper airway, starting between 24 and 48 hours of their inclusion in this study protocol;

3. Presence of runny nose classification moderate or severe (score 2 or 3), according the responsible evaluation;

4. Presence of nasal congestion classification moderate or severe (score 2 or 3), according the responsible evaluation.

Exclusion Criteria:

1. Patients younger than 2 years or percentile for body weight and/or height less than 25;

2. History of nasal obstruction in chronic rhinosinusitis and / or nasal polyposis;

3. Oral chronic respirator with history for six months;

4. Personal history of nasal surgery that in the opinion of the investigator can influence the resistance to nasal airflow;

5. Patients who have a clinical history confirmed (diagnosed) with asthma;

6. Patients under medicine treatment for chronic allergy;

7. Patients with gastroesophageal reflux disease;

8. Presence of psychiatric illness of any kind;

9. Presence of mental retardation from any cause;

10. Diagnosis of renal or hepatic failure;

11. Patients with genetic syndromes;

12. History of hypersensitivity to (s) drug (s) of study or their excipients;

13. Use of prohibited medicine within the prescribed period before the V0 - Inclusion Visit (Table 1);

14. Patients who participated in the last 12 months, of clinical trials protocols;

15. Patients who didn´t updated vaccine book;

16. Relatives of sponsor´s or study site´s employee;

17. Suggestive signs of bacterial infection of upper airways at rhinoscopy, otoscopy or oroscopy;

18. Presence of anemic/inflamed turbinate at anterior rhinoscopy;

19. Presence of septal deviation grade II and III (in any region and any nasal cavity) and / or nasal polyps, or other conditions determinants of nasal obstruction;

20. Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;

21. Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation;

22. Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.

Related Conditions & MeSH terms

• Inflammation
• Nasal Congestion and Inflammations
• Rhinitis

Intervention

Drug:
• brompheniramine + phenylephrine
Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient. OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient.
• Brompheniramine + pseudoephedrine
Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient

Locations

Country	Name	City	State
Brazil	Ache Laboratorios Farmaceuticos	Guarulhos	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Ache Laboratorios Farmaceuticos S.A.

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of nasal congestion and runny nose, after 48 hours of treatment	Improvement is defined as a reduction of at least one point on the rating scale, in both nasal symptoms, after 48 hours of treatment.; Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.	48 hours after single dose of double-blind treatment
Secondary	Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching)		After 2 and 5 (± 1) days of treatment
Secondary	Clinical score of upper airway compromise		After 2 and 5 (± 1) days of treatment
Secondary	Proportion of subjects who used at least once the rescue medication		Within 2 days and the period of 5 (± 1) days of treatment
Secondary	Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.	Collection of safety data throughout the whole study period	Will be evaluated during the 5(± 1) days of treatment